Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with...

Related Keywords

United States ,American ,Rabia Gurses Ozden ,Donald Notman ,Pravin Dugel ,Mark Gallardo ,Joyce Allaire ,Allergan ,Exchange Commission ,American Society Of Cataract ,Ocular Therapeutix Inc ,Linkedin ,Nasdaq ,Intraocular Pressure ,Retinal Disease Highlighted ,Refractive Surgery ,Chief Medical Officer ,Study Investigator ,Glaucoma Specialist ,Travoprost Intracameral Implant ,Open Angle Glaucoma ,Ocular Hypertension ,Executive Chairman ,Ocular Therapeutix ,Age Related Macular Degeneration ,Safety Information ,Looking Statements ,Private Securities Litigation Reform Act ,Special Protocol Assessment ,Nasdaq Ocul ,Nc ,